Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Last update: Oct 3, 7:25 PM
Comments
Loading...
Tempest Therapeutics Analyst Ratings and Price Targets | NASDAQ:TPST | Benzinga
Tempest Therapeutics Inc has a consensus price target of $11.8 based on the ratings of 5 analysts. The high is $16 issued by HC Wainwright & Co. on April 10, 2025. The low is $5 issued by Piper Sandler on November 13, 2024. The 3 most-recent analyst ratings were released by Scotiabank, HC Wainwright & Co., and Scotiabank on April 10, 2025, April 10, 2025, and March 28, 2025, respectively. With an average price target of $10.67 between Scotiabank, HC Wainwright & Co., and Scotiabank, there's an implied 0.47% upside for Tempest Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
HC Wainwright & Co.
Piper Sandler
Jefferies
Ladenburg Thalmann
1calculated from analyst ratings
Analyst Ratings for Tempest Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
04/10/2025 | -15.23% | Scotiabank | $7 → $9 | Downgrade | Sector Outperform → Sector Perform | |||
04/10/2025 | 50.7% | HC Wainwright & Co. | $16 → $16 | Downgrade | Buy → Neutral | |||
03/28/2025 | -34.07% | Scotiabank | $13 → $7 | Maintains | Sector Outperform | |||
03/28/2025 | 50.7% | HC Wainwright & Co. | $47 → $16 | Maintains | Buy | |||
11/13/2024 | -52.91% | Piper Sandler | $8 → $5 | Maintains | Overweight | |||
11/13/2024 | 342.69% | HC Wainwright & Co. | $47 → $47 | Reiterates | Buy → Buy | |||
10/10/2024 | 342.69% | HC Wainwright & Co. | $47 → $47 | Reiterates | Buy → Buy | |||
08/15/2024 | 342.69% | HC Wainwright & Co. | $47 → $47 | Reiterates | Buy → Buy | |||
06/21/2024 | -24.65% | Piper Sandler | $8 → $8 | Reiterates | Overweight → Overweight | |||
06/20/2024 | 342.69% | HC Wainwright & Co. | $47 → $47 | Reiterates | Buy → Buy | |||
05/13/2024 | 342.69% | HC Wainwright & Co. | $47 → $47 | Reiterates | Buy → Buy | |||
05/10/2024 | 342.69% | HC Wainwright & Co. | $47 → $47 | Reiterates | Buy → Buy | |||
03/20/2024 | 342.69% | HC Wainwright & Co. | $47 → $47 | Reiterates | Buy → Buy | |||
03/14/2024 | 22.45% | Scotiabank | → $13 | Initiates | → Sector Outperform | |||
03/13/2024 | 22.45% | Scotiabank | → $13 | Initiates | → Sector Outperform | |||
03/12/2024 | 342.69% | HC Wainwright & Co. | $47 → $47 | Maintains | Buy | |||
02/08/2024 | 41.28% | Jefferies | → $15 | Initiates | → Buy | |||
10/11/2023 | 342.69% | HC Wainwright & Co. | $35 → $47 | Maintains | Buy | |||
08/11/2023 | 229.66% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy | |||
06/05/2023 | 229.66% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy | |||
05/30/2023 | 229.66% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy | |||
05/11/2023 | 229.66% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy | |||
04/28/2023 | 31.86% | Ladenburg Thalmann | $8 → $14 | Maintains | Buy | |||
03/23/2023 | -43.49% | Piper Sandler | $10 → $6 | Maintains | Overweight | |||
03/23/2023 | 229.66% | HC Wainwright & Co. | → $35 | Reiterates | → Buy | |||
02/08/2023 | 229.66% | HC Wainwright & Co. | → $35 | Maintains | Buy |
FAQ
What is the target price for Tempest Therapeutics (TPST) stock?
The latest price target for Tempest Therapeutics (NASDAQ:TPST) was reported by Scotiabank on April 10, 2025. The analyst firm set a price target for $9.00 expecting TPST to fall to within 12 months (a possible -15.57% downside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tempest Therapeutics (TPST)?
The latest analyst rating for Tempest Therapeutics (NASDAQ:TPST) was provided by Scotiabank, and Tempest Therapeutics downgraded their sector perform rating.
When was the last upgrade for Tempest Therapeutics (TPST)?
There is no last upgrade for Tempest Therapeutics
When was the last downgrade for Tempest Therapeutics (TPST)?
The last downgrade for Tempest Therapeutics Inc happened on April 10, 2025 when Scotiabank changed their price target from $7 to $9 for Tempest Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Tempest Therapeutics (TPST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tempest Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tempest Therapeutics was filed on April 10, 2025 so you should expect the next rating to be made available sometime around April 10, 2026.
Is the Analyst Rating Tempest Therapeutics (TPST) correct?
While ratings are subjective and will change, the latest Tempest Therapeutics (TPST) rating was a downgraded with a price target of $7.00 to $9.00. The current price Tempest Therapeutics (TPST) is trading at is $10.66, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
